ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Regístrate

¿Ya eres miembro? Iniciar sesión

Los Principales Corredores en Línea

Más Corredores en Línea

Datos
Noticias
Herramientas
Mercados
Descubrir

Hot Features

Follow Feed

Conéctese con traders e inversores en nuestra comunidad Follow Feed.

Flujo de Opciones

Explora datos de opciones completos y utiliza filtros avanzados con Options Flow.

Monitor

Organiza y monitorea tu lista de seguimiento de acciones y activos con Monitor.
Iniciar Sesión Premium IconPremium Help Menu
S&P 500
5,306.04
0.02%
Dow Jones
38,852.86
-0.55%
US Dollar vs MXN
16.78992
0.75%
Brent Oil
84.325
1.79%
Bitcoin
68,450.24
-1.36%
Registration Strip Icon for charts Regístrate para obtener gráficos en tiempo real, herramientas de análisis y precios.
Regístrate
  1. Inicio
  2. Invertir
  3. Acciones
  4. Estados Unidos
  5. NASDAQ
  6. Candel Therapeutics Inc (CADL)

  7. Candel Therapeutics Inc (CADL) Noticias

CADL

Candel Therapeutics (CADL)

Candel Therapeutics Inc
Fecha:
Ordernar por:
 Showing the most relevant articles for your search:NASDAQ:CADL
FechaHoraFuenteTítuloSímboloCompañía
24/05/202406:30Edgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:CADLCandel Therapeutics Inc
23/05/202416:05Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CADLCandel Therapeutics Inc
23/05/202416:00GlobeNewswire Inc.Candel Therapeutics Reports Prolonged Overall Survival in Phase 2 Clinical Trial of CAN-2409 for Advanced Non-Small Cell Lung Cancer (NSCLC) in Patients Non-Responsive to Immune Checkpoint Inhibitor (ICI) Treatment at 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
22/05/202407:00GlobeNewswire Inc.Candel Therapeutics to Present at the Jefferies Global Healthcare ConferenceNASDAQ:CADLCandel Therapeutics Inc
20/05/202407:00GlobeNewswire Inc.Candel Therapeutics to Host Non-Small Cell Lung Cancer (NSCLC) R&D Breakfast Panel During 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
14/05/202407:30Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CADLCandel Therapeutics Inc
14/05/202407:00GlobeNewswire Inc.Candel Therapeutics Reports First Quarter 2024 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
25/04/202407:00GlobeNewswire Inc.Candel Therapeutics Announces Upcoming Presentations at the 2024 ASCO Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
11/04/202408:00GlobeNewswire Inc.Candel Therapeutics Receives FDA Orphan Drug Designation for CAN-2409 for the Treatment of Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
09/04/202407:00GlobeNewswire Inc.Candel Therapeutics Presents Preclinical Data at AACR on Immunotherapy Candidate for Induction of Tertiary Lymphoid Structures in Solid TumorsNASDAQ:CADLCandel Therapeutics Inc
04/04/202407:00GlobeNewswire Inc.Candel Therapeutics Announces Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
28/03/202415:05GlobeNewswire Inc.Candel Therapeutics Announces Oral Presentation During the 5th Glioblastoma Drug Development Summit with Update on Phase 1b Clinical Trial of CAN-3110 in Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
28/03/202407:05GlobeNewswire Inc.Candel Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
05/03/202415:30GlobeNewswire Inc.Candel Therapeutics Announces an Upcoming Presentation at the AACR Annual Meeting Unveiling New Cancer Immunotherapy CandidateNASDAQ:CADLCandel Therapeutics Inc
13/02/202406:30GlobeNewswire Inc.CAN-3110 Receives FDA Fast Track Designation for Treatment of Recurrent High-Grade GliomaNASDAQ:CADLCandel Therapeutics Inc
05/02/202407:00GlobeNewswire Inc.Candel Therapeutics Sets Path to Success: Recent Achievements Pave the Way for a Promising 2024 Propelled by Key Value Drivers and CatalystsNASDAQ:CADLCandel Therapeutics Inc
19/01/202407:30Edgar (US Regulatory)Form 3 - Initial statement of beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
12/12/202307:58Dow Jones NewsCandel Therapeutics Shares Soar After FDA Fast Track of CAN-2409NASDAQ:CADLCandel Therapeutics Inc
12/12/202307:00GlobeNewswire Inc.Candel Therapeutics Receives FDA Fast Track Designation for CAN-2409 in Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
30/11/202316:00Edgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:CADLCandel Therapeutics Inc
28/11/202308:00GlobeNewswire Inc.Candel Therapeutics Announces Restructuring to Prioritize Resources on Key Value Drivers for Expanded Development of CAN-3110, the enLIGHTEN™ Discovery Platform, and Key Clinical Readouts for CAN-2409NASDAQ:CADLCandel Therapeutics Inc
09/11/202307:00GlobeNewswire Inc.Candel Therapeutics Reports Third Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
04/11/202307:00GlobeNewswire Inc.Candel Therapeutics Presents Preclinical Data from its enLIGHTEN™ Discovery Platform at SITCNASDAQ:CADLCandel Therapeutics Inc
03/11/202311:00GlobeNewswire Inc.Candel Therapeutics Announces Initial Positive Interim Data from Randomized Phase 2 Clinical Trial of CAN-2409 in Non-Metastatic Pancreatic CancerNASDAQ:CADLCandel Therapeutics Inc
18/10/202310:00GlobeNewswire Inc.Candel Therapeutics Announces Nature Publication Showing Extended Survival Associated with Immune Activation in Patients with Recurrent High-Grade Glioma Treated with CAN-3110NASDAQ:CADLCandel Therapeutics Inc
27/09/202308:40GlobeNewswire Inc.Candel Therapeutics Announces Three Abstracts Accepted for Poster Presentations at SITC 2023 Annual MeetingNASDAQ:CADLCandel Therapeutics Inc
26/09/202307:00GlobeNewswire Inc.Candel Therapeutics Reports Encouraging Initial Survival Data from Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung CancerNASDAQ:CADLCandel Therapeutics Inc
06/09/202307:00GlobeNewswire Inc.Candel Therapeutics to Participate in the H.C. Wainwright 25th Annual Global Investment ConferenceNASDAQ:CADLCandel Therapeutics Inc
10/08/202307:00GlobeNewswire Inc.Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate HighlightsNASDAQ:CADLCandel Therapeutics Inc
02/08/202307:00GlobeNewswire Inc.Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth ConferenceNASDAQ:CADLCandel Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:CADL

Su Consulta Reciente

EU
FR0013210465
Republic of France O A T...
NASDAQ
SHPH
Shuttle Pharmaceuticals
LSE
51LR
Westpac B Frn29
BMF
JAPN24
JAPN24 - Julho 2024
IDCM
UTNPBTC
UTN-P: Universa Token
NASDAQ
CHRK
Cherokee
LSE
ZO68
Whitbread G 27
COIN
ADAXUST
ADAX
BIT
SAMDS5
Societe Generale Effekten
BOV
PETRK291
PETRK291 Ex:26,34
GATE
RENBTCBTC
renBTC
LSE
QK19
Morg.st.b.v 24
NYSE
BWY
LSE
QH00
Morg.st.b.v 26
LSE
LNX
Lennox
COIN
MDCNBTC
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

México
Empresa
Negocios
Popular
Obtener la aplicación
App Store
Google Play

Soporte: (55) 4170 8128 | soporte@advfn.mx

Al acceder a los servicios disponibles de ADVFN usted acepta quedar sujerto a los Términos y Condiciones

© 2024 ADVFN PLC - Todos los derechos reservados